Company: FTII
Filing Date: 2025-08-18
Form Type: 8-K
Source: 0001641172-25-024668
Chunk: 0

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-18
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01. Entry into a Material Agreement

As
previously disclosed, on August 12, 2025, FutureTech II Acquisition Corp., a Delaware corporation (the “ Company”), entered
into an Amended and Restated Agreement and Plan of Merger (the “ Merger Agreement”), by and among the Company, Longevity Biomedical,
Inc., a Delaware corporation (“ Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary
of the Company (“ Merger Sub”), and Andrew Leo, solely in the capacity as seller representative.

The
Merger Agreement provides that (i) Longevity will consummate Target Acquisitions (as defined below) upon the terms and subject to conditions
set forth therein and pursuant to the Target Acquisition Agreements (as defined in the Merger Agreement), and (ii) immediately following
the consummation of the Target Acquisitions, the Company will merge with and into PubCo (the “ Reorganization Merger”) with
PubCo as the surviving company of the Reorganization Merger, and (iii) immediately following the consummation of the Reorganization Merger,
Longevity will merge with and into Merger Sub (the “ Acquisition Merger”) with Longevity as the surviving company of the Acquisition
Merger. Following the Acquisition Merger, Longevity will be a wholly-owned subsidiary of PubCo. At the closing of the Transactions (the
“ Closing”), PubCo’s common stock, par value $0.0001 per share (the “ PubCo Common Stock”), is expected to
list on the Nasdaq Stock Market LLC (“ Nasdaq”) under the ticker symbol “ LBIO.” The date on which the Closing
actually occurs is hereinafter referred to as the “ Closing Date.”

Pursuant
to the Merger Agreement, Longevity shall, prior to the closing of the Reorganization Merger, consummate the Target Acquisitions upon
the terms and subject to conditions set forth therein and pursuant to the Target Acquisition Agreements. The Target Acquisitions are
the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue, LLC (“ Aegeria”) pursuant to each
of the Cerevast Acquisition Agreement and the Aegeria Acquisition Agreement, each in accordance with the respective terms thereof.

On
August 12, 2025, the Company consented (the “ Approval of Waiver”) to Longevity entering into a waiver